1.Chemotherapy for Colorecal Cancer.
Journal of the Korean Medical Association 2002;45(7):833-841
There has been a dramatic change in the chemotherapy of colorectal cancer over the years. It has been clearly demonstrated that chemotherapy of patients with metastatic colorectal cancer is associated with survival prolongation and relief of tumor-related symptoms. The optimal use of 5-fluorouracil (5-FU) in combination with folinic acid (FA), the new drugs such as irinotecan and oxaliplatin, and the oral fluoropyrimidines UFT and capecitabine increased therapeutic options and improved outcome of patients with metastatic colorectal cancer. Combination of irinotecan or oxaliplatin and 5-FU/FA is more active than 5-FU/FA. The oral agents capecitabine and UFT/FA seem to have a comparable activity to intravenous bolus 5-FU/FA with improved patients' tolerance. By the early 1990s, the role of postoperative adjuvant chemotherapy in stage III colon cancer had been firmly established. 5-FU-based chemotherapy has been shown to reduce recurrence and improve survival in patients with stage III colon cancer. However, the use of adjuvant therapy is still debated in stage II colon cancer. At present, 6 months, treatment of 5-FU/FA is the standard adjuvant drug combination. New drugs that have been shown to be active in metastatic colorectal cancer, such as irinotecan, oxaliplatin, and oral fluoropyrimidines, hold promise and are being tested in adjuvant settings. New agents acting on novel molecular targets such as epidermal growth factor receptor inhibitors are expected to play a unique role in the treatment of colorectal cancer in the future.
Capecitabine
;
Chemotherapy, Adjuvant
;
Colonic Neoplasms
;
Colorectal Neoplasms
;
Drug Therapy*
;
Fluorouracil
;
Humans
;
Leucovorin
;
Receptor, Epidermal Growth Factor
;
Recurrence
3.The value of fine needle aspiration cytopuncture in diagnosis of hepatocellular carcinoma.
Journal of Medical and Pharmaceutical Information 2005;0(12):33-36
In this study, fine needle aspiration cytopuncture (FNAC) was done for 220 patients with liver tumors. The findings showed that FNAC was of high value in diagnosis of Hepatocellular Carcinoma (HCC). Successful first time of FNAC was 93.2%. The accurate rate 97.7%, sensitivity 97.3% and specificity 100%. 19.6% patients were in well differentiated; 47.7% average differentiated and 32.7% poor differentiated. 86.7% tumor under 3cm in diameter with well-differentiation and 86.7% tumor over 9cm in diameter with poor-differentiated. The FNAC is simple, easy performing and safe method
Carcinoma, Hepatocellular, Diagnosis
4.The 6th Report of the Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure.
Korean Circulation Journal 1998;28(1):123-123
No abstract available.
Hypertension*
;
Joints*
5.A Case of Prolapse of the Bladder.
Korean Journal of Urology 1975;16(1):51-54
Prolapse of the bladder is a rather unusual occurrence and only comparatively few cases have been reported in the literature. A case of prolapse of the bladder through the urethra occurred in a 9-month-old girl was presented. In this case, the bladder was protruded through the urethra probably due to straining following diarrhea and formed an egg-sized prolapsed mass outside the urethra. The literatures were briefly reviewed.
Diarrhea
;
Female
;
Humans
;
Infant
;
Prolapse*
;
Urethra
;
Urinary Bladder*
6.Treatment of Hypertension: Drug Therapy.
Korean Circulation Journal 1997;27(3):350-360
No abstract available.
Drug Therapy*
;
Hypertension*
7.Clinical Application of Radioisotope Hypaque-I 131 Renogram.
Korean Journal of Urology 1964;5(1):57-62
Since 1954. radioisotope renography has been performed as a useful kidney function test in the urological field The author using Hypaque-I which has no liver interference, performed radioisotope renography on 25 cases, in which 10 cases of normal, 5 cases of obstructive uropathy, 7 cases of renal dysfunction, 1 case of acute glomerulonephritis and 2 cases of hypertensive uropathy were included In the normal cases, the Hypaque-I renogram has 3 typical segments, namely vascular segment, functional segment and evacuation phase. The vascular segment begins 8~20 seconds after a rapid intravenous injection of Hypaque-I, lasting 30-40 seconds and occurs the functional segment. The functional segment is completed within 3~10 minuets, having a peak And then, the evacuation phase appears, inclining down rapidly. In the renogram of obstructive uropathy, the vascular and functional segments are almost normal together, but the evacuation phase is either prolonged or increased In the renogram of renal dysfunction, the vascular segment is not only reduced, but also the functional segment is low and the evacuation phase shows a dull inclining curve. In the renogram of acute glomerulonephritis, shows no changes of each segment. The renogram of hypertensive uropathy represents the remarkably lower vascular and functional segments and evacuation phase than those of renal dysfunction. The Hypaque-I renogram has many practical advantage, offering rapid and immediate results, being easily performed, being non-traumatic and innocuous, making each kidney to be tested separately, being able to be repeated frequently, and being free from any preparation and anesthesia of patients.
Anesthesia
;
Glomerulonephritis
;
Humans
;
Injections, Intravenous
;
Kidney
;
Kidney Function Tests
;
Liver
;
Radioisotope Renography
8.Herpes simplex.
Journal of the Korean Medical Association 1998;41(8):855-860
No abstract available.
Herpes Simplex*
9.Control of Signal Transduction Pathway.
Journal of the Korean Medical Association 1998;41(8):824-828
No abstract available.
Signal Transduction*
10.Thymosin-a 1 for treatment of chronic hepatitis B
Journal of Medical and Pharmaceutical Information 2004;0(7):21-24
A study on 56 patients with chronic hepatitis B who were divided into 2 groups: study group and control group. The study group including 31 patients was treated with Thymosin-α1 1.6mg/day, twice a week for 6 months. The control group with 25 patients of same clinical data was treated with common liver-protective drugs. Both groups were monitored and assessed after 24 months. The results showed that the study group with treatment of Thymosin-α1 is better than control one in all aspects of ALT normalization, sero-conversion and decrease of HBV-DNA<5 copies/ml
Hepatitis B, Chronic
;
Therapeutics